Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1989437 | 1.00 | PPM1D (0.35) | PPM1DNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL18049618 | 1.00 | PPM1D (0.35) | PPM1DNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL7464146 | 0.89 | NPY1R (0.38) | PPM1DNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL5380480 | 0.89 | NPY1R (0.38) | PPM1DNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL7464139 | 0.89 | NPY1R (0.38) | PPM1DNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL5380476 | 0.89 | NPY1R (0.38) | PPM1DNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL5380472 | 0.89 | NPY1R (0.38) | PPM1DNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL13573044 | 0.85 | NPY1R (0.41) | PPM1DNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL13573064 | 0.83 | NPY1R (0.40) | PPM1DNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL13573075 | 0.83 | NPY1R (0.40) | PPM1DNPY1RNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20220306634-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA SAN DIEGO, INC. | 2022-09-29 | — | — | US | disclosed |
| EP-3825316-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2021-05-26 | — | — | EP | disclosed |
| EP-3489236-B1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-30 | — | — | EP | disclosed |
| EP-3489236-A1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | Takeda Pharmaceutical Company Limited (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-2902392-B1 | Fused heteroaromatic pyrrolidinones as syk inhibitors | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-20180141951-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | CALITHERA BIOSCIENCES, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20180141951-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | CALITHERA BIOSCIENCES, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20150336964-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-26 | — | — | US | disclosed |
| EP-2902392-A1 | Fused heteroaromatic pyrrolidinones as syk inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2015-08-05 | — | — | EP | disclosed |
| EP-2516434-B1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-20130245031-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245031-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2013-09-19 | — | — | US | disclosed |
| US-8440689-B2 | Fused heteroaromatic pyrrolidinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-14 | — | — | US | disclosed |
| US-8440689-B2 | Fused heteroaromatic pyrrolidinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20130116260-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116260-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306634-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | PPM1D 395/4885NPY1R 801/4885NPY2R 1424/4885 |
| US-20180141951-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | PPM1D 395/4885NPY1R 801/4885NPY2R 1424/4885 |
| US-20130116260-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | SYK, BTK, LYN | PPM1D 280/4885NPY1R 1261/4885NPY2R 2059/4885 |
| US-20130245031-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | PPM1D 395/4885NPY1R 801/4885NPY2R 1424/4885 |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | PPM1D 395/4885NPY1R 801/4885NPY2R 1424/4885 |
| US-20150336964-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | PPM1D 395/4885NPY1R 801/4885NPY2R 1424/4885 |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | PPM1D 395/4885NPY1R 801/4885NPY2R 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.